Overview

LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma

Status:
Terminated
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is determine whether the combination therapy with LEE011 and chemoembolization in patients with locally advanced Hepatocellular Carcinoma not amenable to curative therapies will provide greater efficacy than chemoembolization alone with a tolerable safety profile.
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
Novartis Pharmaceuticals